Brief: Mateon's C001- Phase 2 Study For OT-101 Against COVID-19 Gets Clearance For Patient Enrollment
04/11/2020 12:43
Nov 4 (Reuters) - Mateon Therapeutics Inc MATN.PK :
* MATEON'S C001- A GLOBAL PHASE 2 STUDY FOR OT-101 AGAINST
COVID-19- RECEIVED CLEARANCE FOR PATIENT ENROLLMENT
Source text for Eikon: ID:nGNX1pjGkR
Further company coverage: MATN.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas